CY1114685T1 - Παρατεταμενη απελευθερωση αντιμολυσματικων αμινογλυκοζιτων - Google Patents
Παρατεταμενη απελευθερωση αντιμολυσματικων αμινογλυκοζιτωνInfo
- Publication number
- CY1114685T1 CY1114685T1 CY20131101075T CY131101075T CY1114685T1 CY 1114685 T1 CY1114685 T1 CY 1114685T1 CY 20131101075 T CY20131101075 T CY 20131101075T CY 131101075 T CY131101075 T CY 131101075T CY 1114685 T1 CY1114685 T1 CY 1114685T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lipid
- patient
- less
- present
- treating
- Prior art date
Links
- 229940126575 aminoglycoside Drugs 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 6
- 150000002632 lipids Chemical class 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000002924 anti-infective effect Effects 0.000 abstract 2
- 239000000356 contaminant Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000007499 fusion processing Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000010899 nucleation Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Εδώ παρέχονται λιπιδικά αντιμολυσματικά σκευάσματα ουσιαστικά ελεύθερα από ανιοντικά λιπίδια με ένα λόγο λιπιδίου προς αντιμολυσματικό να είναι περίπου 1:1 έως περίπου 4:1, και μια μέση κατά μέσο όρο διάμετρο μικρότερη από περίπου 1 μm. Επίσης παρέχεται μια μέθοδος παρασκευής ενός λιπιδικού αντι-μολυσματικού σκευάσματος περιλαμβάνουσα μια διεργασία έγχυσης. Επίσης παρέχονται λιπιδικά αντιμολυ-σματικά σκευάσματα όπου ο λόγος λιπιδίου προς φάρμακο είναι περίπου 1:1 ή λιγότερο, περίπου 0,75:1 ή λιγότερο, ή περίπου 0,50:1 ή λιγότερο παρασκευαζόμενα με μια διεργασία σύντηξης εν σειρά. Η παρούσα εφεύρεση αναφέρεται επίσης σε μια μέθοδο θεραπείας ενός ασθενή με μια πνευμονική λοίμωξη η οποία μέθοδος περιλαμβάνει τη χορήγηση στον ασθενή μιας θεραπευτικώς αποτελεσματικής ποσότητας από ένα λιπιδικό αντιμολυσματικό σκεύασμα της παρούσας εφεύρεσης. Η παρούσα εφεύρεση αναφέρεται επίσης σε μια μέθοδο θεραπείας ενός ασθενή για κυστική ίνωση η οποία μέθοδος περιλαμβάνει τη χορήγηση στον ασθενή μιας θεραπευτικώς αποτελεσματικής ποσότητας από ένα λιπιδικό αντιμολυσματικό σκεύασμα της παρούσας εφεύρεσης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/185,448 US7718189B2 (en) | 2002-10-29 | 2005-07-19 | Sustained release of antiinfectives |
EP06787716.7A EP1909759B2 (en) | 2005-07-19 | 2006-07-19 | Sustained release of antiinfective aminoglycosides |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114685T1 true CY1114685T1 (el) | 2016-10-05 |
Family
ID=37669512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101075T CY1114685T1 (el) | 2005-07-19 | 2013-11-29 | Παρατεταμενη απελευθερωση αντιμολυσματικων αμινογλυκοζιτων |
Country Status (26)
Country | Link |
---|---|
US (7) | US7718189B2 (el) |
EP (2) | EP1909759B2 (el) |
JP (6) | JP5415759B2 (el) |
KR (2) | KR101437338B1 (el) |
CN (2) | CN103263387B (el) |
AU (1) | AU2006270008B2 (el) |
BR (1) | BRPI0613865A2 (el) |
CA (2) | CA2614764C (el) |
CR (1) | CR9736A (el) |
CY (1) | CY1114685T1 (el) |
DK (1) | DK1909759T3 (el) |
EC (1) | ECSP088175A (el) |
ES (1) | ES2437866T5 (el) |
HK (1) | HK1124770A1 (el) |
HN (1) | HN2008000084A (el) |
IL (3) | IL188406A0 (el) |
ME (1) | ME00597B (el) |
MX (1) | MX2008000425A (el) |
NZ (1) | NZ565300A (el) |
PL (1) | PL1909759T3 (el) |
PT (1) | PT1909759E (el) |
RS (1) | RS20080019A (el) |
RU (1) | RU2438655C2 (el) |
SI (1) | SI1909759T1 (el) |
WO (1) | WO2007011940A2 (el) |
ZA (1) | ZA200800367B (el) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
ES2439727T3 (es) * | 2002-10-29 | 2014-01-24 | Insmed Incorporated | Liberación sostenida de antiinfectantes |
US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
TWI395591B (zh) * | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白(muc-1)疫苗 |
US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
US7618651B2 (en) * | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
US7854943B2 (en) * | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
CA2838111C (en) | 2005-12-08 | 2016-01-19 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
ES2668554T3 (es) * | 2006-04-06 | 2018-05-18 | Insmed Incorporated | Métodos para la encapsulación liposomal inducida por coacervación y sus formulaciones |
US20080107723A1 (en) * | 2006-09-28 | 2008-05-08 | Perkins Walter R | Methods of Treating Pulmonary Distress |
US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8071127B2 (en) * | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US20100196455A1 (en) * | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
EP2200613B1 (en) * | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
AU2008316841B2 (en) * | 2007-10-23 | 2014-04-17 | Insmed Incorporated | Liposomal vancomycin formulations |
CN102166191A (zh) * | 2011-04-15 | 2011-08-31 | 四川大学 | 盐酸米诺环素控释纳米脂质体及其制备方法与用途 |
EP2720680B1 (en) * | 2011-06-17 | 2020-02-12 | Berg LLC | Inhalable pharmaceutical compositions |
ES2532667T3 (es) | 2011-09-12 | 2015-03-30 | Meiji Seika Pharma Co., Ltd. | Composiciones acuosas que contienen arbekacina |
CN108743537B (zh) * | 2012-05-21 | 2021-06-11 | 英斯麦德公司 | 治疗肺部感染的系统 |
US9820940B2 (en) * | 2012-08-17 | 2017-11-21 | University Of Houston System | Liposomal formulations of polymyxin and uses thereof |
US10092515B2 (en) * | 2012-08-17 | 2018-10-09 | University Of Houston System | Liposomal formulations of polymyxin B and uses thereof |
CN104884047A (zh) | 2012-11-29 | 2015-09-02 | 英斯梅德股份有限公司 | 稳定的万古霉素制剂 |
US9662345B2 (en) * | 2013-06-14 | 2017-05-30 | Professional Compounding Centers Of America | Antibiotic composition for inhalation and irrigation |
EP3021920A4 (en) * | 2013-07-17 | 2017-04-05 | Insmed Incorporated | Low resistance aerosol exhalation filter |
DE102013214636A1 (de) * | 2013-07-26 | 2015-01-29 | Heraeus Medical Gmbh | Bioresorbierbare Werkstoffverbunde, enthaltend Magnesium und Magnesiumlegierungen sowie Implantate aus diesen Verbunden |
WO2015017807A1 (en) * | 2013-08-01 | 2015-02-05 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
EP3060198A4 (en) | 2013-10-22 | 2017-06-28 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
CN103585109A (zh) * | 2013-11-20 | 2014-02-19 | 河南牧翔动物药业有限公司 | 一种头孢喹诺脂质体及其制备方法 |
US20160120806A1 (en) * | 2014-04-08 | 2016-05-05 | Aradigm Corporation | Nanocrystals formed in a microenvironment |
CA2943049A1 (en) | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
MX2016014921A (es) | 2014-05-15 | 2017-07-28 | Insmed In Incorporated | Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas. |
CN104873463A (zh) * | 2015-03-06 | 2015-09-02 | 朱孝云 | 用于治疗肺部感染的1-N-乙基庆大霉素Cla或其衍生物新制剂 |
GB201511058D0 (en) * | 2015-06-23 | 2015-08-05 | Lamellar Biomedical Ltd | Compositions and methods for using lamellar bodies for therapeutic purposes |
CN107823695B (zh) * | 2017-09-19 | 2022-03-15 | 华东理工大学 | 一种智能型抗菌敷料及其制备方法 |
EP4137123A1 (en) * | 2018-01-02 | 2023-02-22 | Scynexis, Inc. | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
JP7391039B2 (ja) | 2018-04-23 | 2023-12-04 | インスパーメッド コーポレーション | 肺疾患の処置に使用するための吸入可能なリポソーム徐放性組成物 |
US20210113595A1 (en) * | 2018-04-30 | 2021-04-22 | Purdue Research Foundation | Liposomal nano formulation of combinational antibiotics and the uses thereof |
KR20210024451A (ko) * | 2018-05-02 | 2021-03-05 | 인스메드 인코포레이티드 | 리포솜 약물 제형을 제조하는 방법 |
AU2019312592A1 (en) | 2018-07-31 | 2021-02-18 | Microbion Corporation | Bismuth-thiol compositions and methods for treating wounds |
MX2021001272A (es) * | 2018-07-31 | 2021-07-15 | Microbion Corp | Composiciones de bismuto-tiol y metodos de uso. |
CN109330992B (zh) * | 2018-12-07 | 2021-04-09 | 中国医科大学 | 一种聚多巴胺修饰纳米结构脂质载体及其在皮内递药中的应用 |
WO2022261174A1 (en) * | 2021-06-09 | 2022-12-15 | Insmed Incorporated | In vitro release assay methods for liposomal aminoglycoside formulations |
Family Cites Families (203)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091572A (en) | 1962-07-16 | 1963-05-28 | Schering Corp | Gentamycin and method of production |
US3136704A (en) | 1962-12-05 | 1964-06-09 | Schering Corp | Manufacture of gentamycin |
US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
GB2046092B (en) * | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
HU184141B (en) * | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
US4451447A (en) * | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
ATE18353T1 (de) | 1981-07-02 | 1986-03-15 | Hoffmann La Roche | Verfahren zur herstellung von liposomenloesungen. |
US4348448A (en) * | 1981-09-08 | 1982-09-07 | Cornell Richard R | Molding strip having a curvilinear surface and a method for making same from laminar sheet material |
US4547490A (en) | 1981-12-31 | 1985-10-15 | Neomed, Inc. | Synthetic whole blood and a method of making the same |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4684625A (en) | 1982-07-08 | 1987-08-04 | Syntex (U.S.A.) Inc. | Method for enhancing the anti-infective activity of muramyldipeptide derivatives |
US5169637A (en) * | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4981692A (en) * | 1983-03-24 | 1991-01-01 | The Liposome Company, Inc. | Therapeutic treatment by intramammary infusion |
US5030453A (en) * | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
CA1237670A (en) * | 1983-05-26 | 1988-06-07 | Andrew S. Janoff | Drug preparations of reduced toxicity |
US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
US4606939A (en) | 1983-06-22 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation |
CA1237671A (en) * | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
GB8322178D0 (en) | 1983-08-17 | 1983-09-21 | Sterwin Ag | Preparing aerosol compositions |
EP0153955A1 (en) | 1983-09-06 | 1985-09-11 | Health Research, Inc. | Liposome delivery method for decreasing the toxicity of an antitumor drug |
US4721612A (en) | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
SE8403905D0 (sv) * | 1984-07-30 | 1984-07-30 | Draco Ab | Liposomes and steroid esters |
US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
WO1986006959A1 (en) | 1985-05-22 | 1986-12-04 | Liposome Technology, Inc. | Liposome inhalation method and system |
US5409704A (en) * | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US4975282A (en) * | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
JP2579625B2 (ja) | 1985-07-05 | 1997-02-05 | ザ リポソ−ム カンパニ−,インコ−ポレイテツド | 改良された取り込み効率を有するマルチラメラリポソ−ム |
JPH0665648B2 (ja) * | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
US4861580A (en) | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US5041278A (en) | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
US5041581A (en) * | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
US5023087A (en) * | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
US4833134A (en) | 1986-08-19 | 1989-05-23 | Takeda Chemical Industries, Ltd. | Cephem compounds |
US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US4933121A (en) * | 1986-12-10 | 1990-06-12 | Ciba Corning Diagnostics Corp. | Process for forming liposomes |
US5320906A (en) * | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
EP0295248B2 (en) | 1986-12-23 | 1999-04-28 | The Liposome Company, Inc. | Liposome preparation and antibiotic |
US5723147A (en) * | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
US4895452A (en) * | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
US5269979A (en) * | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
BE1001869A3 (fr) * | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
US4952405A (en) * | 1988-10-20 | 1990-08-28 | Liposome Technology, Inc. | Method of treating M. avium infection |
US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5820848A (en) * | 1990-01-12 | 1998-10-13 | The Liposome Company, Inc. | Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
JPH05507090A (ja) | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | 直接噴霧乾燥された薬剤/脂質粉末組成物 |
US5614216A (en) | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
IT1245761B (it) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
US5770563A (en) | 1991-12-06 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof |
US6001644A (en) | 1991-12-17 | 1999-12-14 | The Regents Of The University Of California | Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5756353A (en) * | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5871710A (en) | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
AU3244393A (en) | 1992-12-02 | 1994-06-22 | Vestar, Inc. | Antibiotic formulation and process |
US5958449A (en) | 1992-12-02 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for bacterial infections |
US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
CA2159596C (en) * | 1993-04-02 | 2002-06-11 | Royden Coe | Method of producing liposomes |
CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
US5759571A (en) * | 1993-05-11 | 1998-06-02 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for drug resistant infections |
DK0707472T3 (da) | 1993-07-08 | 2001-04-17 | Liposome Co Inc | Fremgangsmåde til regulering af størrelsen af liposomer |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
JPH09506866A (ja) | 1993-12-14 | 1997-07-08 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 医薬として活性のある物質の免疫療法のための放出制御 |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US5610198A (en) | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
US5550109A (en) * | 1994-05-24 | 1996-08-27 | Magainin Pharmaceuticals Inc. | Inducible defensin peptide from mammalian epithelia |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
SA95160463B1 (ar) | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
US5662929A (en) | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
US5972379A (en) | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
US5855610A (en) | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
IL120317A (en) | 1995-06-06 | 2000-08-13 | Bayer Ag | Ciprofloxacin-hydrocortisone suspension |
US5643599A (en) * | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
WO1996041818A1 (en) | 1995-06-09 | 1996-12-27 | Drohan William N | Chitin hydrogels, methods of their production and use |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
EP0856026A1 (en) | 1995-10-19 | 1998-08-05 | Receptagen Corporation | Discrete-length polyethylene glycols |
GB9602969D0 (en) | 1996-02-13 | 1996-04-10 | The Technology Partnership Plc | Liquid supply apparatus |
US5840702A (en) | 1996-03-22 | 1998-11-24 | Uab Research Foundation | Cystic fibrosis treatment |
US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
WO1997040835A1 (en) * | 1996-04-26 | 1997-11-06 | Magainin Pharmaceuticals Inc. | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6503881B2 (en) | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
JP2001501173A (ja) * | 1996-08-23 | 2001-01-30 | アルザ コーポレイション | シスプラチン化合物を含有するリポソーム |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
US6451784B1 (en) * | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
ES2285743T3 (es) * | 1996-12-30 | 2007-11-16 | Battelle Memorial Institute | Uso de un farmaco anticancerigeno no encapsulado para la preparacion de una formulacion para tratar neoplasias mediante inhlacion. |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
KR20060066753A (ko) | 1997-10-22 | 2006-06-16 | 젠스 포니카우 | 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도 |
US6051251A (en) * | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
BR9911071A (pt) | 1998-05-27 | 2001-02-06 | Euro Celtique Sa | Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
CA2340118C (en) | 1998-08-12 | 2009-01-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
ATE353630T1 (de) * | 1998-11-12 | 2007-03-15 | Transave Inc | Inhalationssystem |
US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
WO2000029103A1 (en) | 1998-11-13 | 2000-05-25 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
CA2355775A1 (en) | 1998-12-17 | 2000-06-22 | Pathogenesis Corporation | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
US6211162B1 (en) * | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
CA2361551A1 (en) | 1999-02-08 | 2000-08-10 | Alza Corporation | Method for controlling liposome size |
US6613352B2 (en) * | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
KR100903243B1 (ko) * | 1999-06-03 | 2009-06-17 | 제시 엘. 에스. 에이유 | 세포증식 및 세포사를 조절하기 위한 방법 및 조성물 |
JP5388395B2 (ja) | 1999-07-15 | 2014-01-15 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 脂質に被包された治療剤の製造方法 |
US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6235177B1 (en) | 1999-09-09 | 2001-05-22 | Aerogen, Inc. | Method for the construction of an aperture plate for dispensing liquid droplets |
DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
AU777338B2 (en) * | 1999-12-04 | 2004-10-14 | Research Development Foundation | Carbon dioxide enhancement of inhalation therapy |
DE60123583T2 (de) | 2000-02-04 | 2007-08-09 | Lipoxen Technologies Ltd. | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
US7100600B2 (en) | 2001-03-20 | 2006-09-05 | Aerogen, Inc. | Fluid filled ampoules and methods for their use in aerosolizers |
US6948491B2 (en) | 2001-03-20 | 2005-09-27 | Aerogen, Inc. | Convertible fluid feed system with comformable reservoir and methods |
US7971588B2 (en) | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
US8336545B2 (en) | 2000-05-05 | 2012-12-25 | Novartis Pharma Ag | Methods and systems for operating an aerosol generator |
US7600511B2 (en) | 2001-11-01 | 2009-10-13 | Novartis Pharma Ag | Apparatus and methods for delivery of medicament to a respiratory system |
US6968840B2 (en) | 2000-05-05 | 2005-11-29 | Aerogen, Inc. | Methods and systems for operating an aerosol generator |
MXPA02010884A (es) | 2000-05-05 | 2003-03-27 | Aerogen Ireland Ltd | Aparato y metodo para el suministro de medicamentos al sistema respiratorio. |
CA2410577A1 (en) * | 2000-05-23 | 2001-12-13 | The Trustees Of Columbia University In The City Of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
US6338859B1 (en) | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
US6521736B2 (en) | 2000-09-15 | 2003-02-18 | University Of Massachusetts | Amphiphilic polymeric materials |
MXPA03003401A (es) | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
US6497901B1 (en) * | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
EP1203614A1 (de) * | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
JP2004522717A (ja) | 2000-12-01 | 2004-07-29 | バイオミラ,インコーポレイテッド | Pegへの注入による大型リポソームの作製 |
WO2002060412A2 (en) * | 2001-02-01 | 2002-08-08 | Board Of Regents | Stabilised polymeric aerosols for pulmonary gene delivery |
DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
US20030060451A1 (en) * | 2001-05-29 | 2003-03-27 | Rajneesh Taneja | Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
EP1269993A1 (en) * | 2001-06-21 | 2003-01-02 | Applied NanoSystems B.V. | Delivery of small hydrophilic molecules packaged into lipid vesicles |
US6991809B2 (en) | 2001-06-23 | 2006-01-31 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
AU2002323151A1 (en) | 2001-08-13 | 2003-03-03 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
US20030096774A1 (en) | 2001-11-21 | 2003-05-22 | Igor Gonda | Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
JP2005525375A (ja) * | 2002-03-05 | 2005-08-25 | トランセイブ, インク. | 生物活性物質をリポソーム又は脂質複合体内に封入する方法 |
CA2491164C (en) | 2002-06-28 | 2012-05-08 | Cory Giesbrecht | Method and apparatus for producing liposomes |
WO2004054499A2 (en) | 2002-08-02 | 2004-07-01 | Transave, Inc. | Platinum aggregates and process for producing the same |
WO2004017944A1 (en) | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
KR100489701B1 (ko) | 2002-10-09 | 2005-05-16 | 주식회사 태평양 | 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법 |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
ES2439727T3 (es) * | 2002-10-29 | 2014-01-24 | Insmed Incorporated | Liberación sostenida de antiinfectantes |
WO2004047802A2 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Liposomal formulations |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
KR20060015265A (ko) | 2003-05-30 | 2006-02-16 | 알자 코포레이션 | 제제의 폐 투여 방법 |
GB2388581A (en) | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
ITRE20030095A1 (it) * | 2003-10-14 | 2005-04-15 | Corghi Spa | Dispositivo stallonatore per macchine smontagomme. |
US20050214224A1 (en) | 2003-11-04 | 2005-09-29 | Nektar Therapeutics | Lipid formulations for spontaneous drug encapsulation |
US7452524B2 (en) | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Method for improvement of tolerance for therapeutically effective agents delivered by inhalation |
US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
JP4452799B2 (ja) | 2004-07-14 | 2010-04-21 | 独立行政法人産業技術総合研究所 | コアセルベートを活用したリポソームの製造方法 |
JP2006263054A (ja) | 2005-03-23 | 2006-10-05 | Konica Minolta Sensing Inc | 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム |
EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
DE102005034403B3 (de) | 2005-07-22 | 2007-02-22 | Airbus Deutschland Gmbh | Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile |
JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
WO2007029138A2 (en) | 2005-09-07 | 2007-03-15 | Philips Intellectual Property & Standards Gmbh | System and method for inductively measuring the bio-impedance of a conductive tissue |
KR100705981B1 (ko) | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물 |
CA2838111C (en) | 2005-12-08 | 2016-01-19 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
ES2668554T3 (es) | 2006-04-06 | 2018-05-18 | Insmed Incorporated | Métodos para la encapsulación liposomal inducida por coacervación y sus formulaciones |
WO2008039989A2 (en) | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8071127B2 (en) | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
WO2008137917A1 (en) | 2007-05-07 | 2008-11-13 | Transave, Inc. | Method of treating bacterial infections with antibacterial formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
UA27298U (en) | 2007-06-13 | 2007-10-25 | Method for preventing pleural empyema after pneumonectomy | |
UA27804U (en) | 2007-07-26 | 2007-11-12 | Method for preventing respiratory complications after surgery in lungs and pleura | |
EP2593110B1 (en) | 2010-07-12 | 2021-01-06 | Xellia Pharmaceuticals ApS | Treatment of lung infections by administration of tobramycin by aerolisation |
EP2457609A1 (en) | 2010-11-24 | 2012-05-30 | PARI Pharma GmbH | Aerosol generator |
CN108743537B (zh) | 2012-05-21 | 2021-06-11 | 英斯麦德公司 | 治疗肺部感染的系统 |
WO2015017807A1 (en) | 2013-08-01 | 2015-02-05 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
-
2005
- 2005-07-19 US US11/185,448 patent/US7718189B2/en active Active
-
2006
- 2006-07-19 EP EP06787716.7A patent/EP1909759B2/en active Active
- 2006-07-19 MX MX2008000425A patent/MX2008000425A/es active IP Right Grant
- 2006-07-19 CA CA2614764A patent/CA2614764C/en active Active
- 2006-07-19 AU AU2006270008A patent/AU2006270008B2/en active Active
- 2006-07-19 NZ NZ565300A patent/NZ565300A/en unknown
- 2006-07-19 WO PCT/US2006/027859 patent/WO2007011940A2/en active Application Filing
- 2006-07-19 KR KR1020137031379A patent/KR101437338B1/ko active IP Right Grant
- 2006-07-19 JP JP2008522895A patent/JP5415759B2/ja active Active
- 2006-07-19 CN CN201310149581.0A patent/CN103263387B/zh active Active
- 2006-07-19 BR BRPI0613865-9A patent/BRPI0613865A2/pt not_active Application Discontinuation
- 2006-07-19 SI SI200631702T patent/SI1909759T1/sl unknown
- 2006-07-19 PL PL06787716T patent/PL1909759T3/pl unknown
- 2006-07-19 KR KR1020087002031A patent/KR101358660B1/ko active IP Right Grant
- 2006-07-19 CA CA2838108A patent/CA2838108C/en active Active
- 2006-07-19 EP EP13175824.5A patent/EP2649988A1/en not_active Withdrawn
- 2006-07-19 CN CN200680034397XA patent/CN101267806B/zh active Active
- 2006-07-19 PT PT67877167T patent/PT1909759E/pt unknown
- 2006-07-19 DK DK06787716.7T patent/DK1909759T3/da active
- 2006-07-19 RU RU2008102651/15A patent/RU2438655C2/ru active
- 2006-07-19 ME MEP-2009-68A patent/ME00597B/me unknown
- 2006-07-19 RS RSP-2008/0019A patent/RS20080019A/sr unknown
- 2006-07-19 ES ES06787716T patent/ES2437866T5/es active Active
-
2007
- 2007-12-25 IL IL188406A patent/IL188406A0/en unknown
-
2008
- 2008-01-11 ZA ZA200800367A patent/ZA200800367B/xx unknown
- 2008-01-18 HN HN2008000084A patent/HN2008000084A/es unknown
- 2008-02-12 EC EC2008008175A patent/ECSP088175A/es unknown
- 2008-02-15 CR CR9736A patent/CR9736A/es unknown
-
2009
- 2009-03-11 HK HK09102316.4A patent/HK1124770A1/xx unknown
-
2010
- 2010-03-29 US US12/748,756 patent/US8802137B2/en not_active Expired - Lifetime
-
2011
- 2011-11-17 IL IL216401A patent/IL216401A/en active IP Right Grant
-
2013
- 2013-07-12 JP JP2013146934A patent/JP5800865B2/ja active Active
- 2013-11-29 CY CY20131101075T patent/CY1114685T1/el unknown
-
2014
- 2014-06-30 US US14/319,018 patent/US9827317B2/en active Active
- 2014-09-26 JP JP2014196130A patent/JP5902782B2/ja active Active
-
2016
- 2016-01-12 JP JP2016003289A patent/JP6125676B2/ja active Active
- 2016-06-05 IL IL246026A patent/IL246026A0/en unknown
-
2017
- 2017-02-17 JP JP2017027482A patent/JP2017082015A/ja not_active Withdrawn
- 2017-10-24 US US15/792,166 patent/US20180104345A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,995 patent/US20190008970A1/en not_active Abandoned
- 2018-11-30 JP JP2018225160A patent/JP2019052170A/ja active Pending
-
2019
- 2019-03-08 US US16/297,027 patent/US20190201534A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,836 patent/US20210121574A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114685T1 (el) | Παρατεταμενη απελευθερωση αντιμολυσματικων αμινογλυκοζιτων | |
van der Maaden et al. | Layer-by-layer assembly of inactivated poliovirus and N-trimethyl chitosan on pH-sensitive microneedles for dermal vaccination | |
CY1119148T1 (el) | Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης | |
CY1123152T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
Mamo et al. | Emerging nanotechnology approaches for HIV/AIDS treatment and prevention | |
ES2761255T3 (es) | Dispositivo de punción | |
CR7362A (es) | Formulaciones farmaceuticas de derivado de platino | |
SMT201300095B (it) | Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia | |
CU20090114A7 (es) | Formulación liposomal y proceso para la preparación del mismo | |
EP4043040A8 (en) | Small liposomes for delivery of immunogen-encoding rna | |
BRPI0509655A (pt) | uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina | |
PA8561401A1 (es) | Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino]quinazolin-6-il}alil) acetamida y procedimiento de produccion | |
CO6470887A2 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona. | |
PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
UY26139A1 (es) | Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos | |
ATE308341T1 (de) | Pharmazeutische formulierungen | |
CY1104977T1 (el) | Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων πα την αντιμετωπιση παθησεων ρευματικης φυσεως | |
Hirschberg et al. | A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus | |
ES2455499T3 (es) | Compuestos neuroprotectores y composiciones farmacéuticas que los comprenden | |
Shakya et al. | A comparative study of microneedle-based cutaneous immunization with other conventional routes to assess feasibility of microneedles for allergy immunotherapy | |
CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
BRPI0417938A (pt) | formulações de proteìnas hidrofóbicas em uma composição imunogênica que possui tolerabilidade aperfeiçoada | |
CY1114251T1 (el) | Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους | |
ES2245004T3 (es) | Inhibicion viral mediante alcoholes, alcanos, acidos grasos y amidas de cadena larga. | |
BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida |